News & Partnering

Press releases

November 11, 2024

Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting

May 21, 2024

Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing

November 20, 2023

Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma

November 10, 2023

Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting

In the News

November 25, 2024 | OncLive

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

November 25, 2024 | OncLive

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

Upcoming Events

None at this time, stay tuned!